- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit Phase IV CT protocol for Entrectinib: CDSCO panel tells Roche India
New Delhi: Rejecting the drug major Roche's alternative proposal to the Phase IV clinical trial of anti-cancer Entrectinib capsules of 100 mg and 200 mg, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has reiterated its earlier recommendation and directed the firm to submit the Phase IV clinical trial protocol before the committee.
This came after the firm presented its request for consideration of an alternative proposal to the Phase IV clinical trial of the anticancer drug Entrectinib 100 and 200 mg capsules.
Entrectinib is a tyrosine kinase inhibitor that acts on several receptors. It functions as an ATP competitor to inhibit tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, TRKC, as well as proto-oncogene tyrosine-protein kinase ROS1 and anaplastic lymphoma kinase (ALK).
TRK receptors produce cell proliferation via downstream signaling through the mitogen activated protein kinase, phosphoinositide 3-kinase, and phospholipase C-γ.4 ALK produces similar signalling with the addition of downstream JAK/STAT activation. Inhibition of these pathways suppresses cancer cell proliferation and shifts the balance in favor of apoptosis resulting in shrinking of tumor volume.
Earlier, the Medical Dialogues Team had reported that drug major, Roche Products had got approval from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to manufacture and market anti-cancer Entrectinib capsules of 100 mg and 200 mg for the treatment of metastatic non-small cell lung cancer.
This approval was subject to the condition that the firm conduct a Phase IV clinical trial in the country in 50 patients, for which the protocol should be submitted to CDSCO within two months of the drug's approval for review by the committee.
Regarding the above condition, at a recent SEC meeting, the firm presented its request for consideration of an alternative proposal to a Phase IV clinical trial.
The committee noted the following alternative proposals to the Phase IV CT study of the firm:
1. The participation of Indian centres in global clinical trials: two Phase III studies would include Indian patients for a total of 18 patients.
2. The voluntary conduct of a Pilot Study for tumors agonistic and rare conditions (TARC): a cohort of additional patients would be recruited from a large apex center which routinely uses NGS screening panel that includes the mutations of interest and from HCPs pan-India in an RWE basket study.
After a detailed assessment, the committee decided to stick with its original recommendation. Accordingly, the committee directed the firm to submit the Phase IV clinical trial protocol before the committee.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.